Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?
- 1 February 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 34 (2), 167-175
- https://doi.org/10.1097/qad.0000000000002397
Abstract
Immune checkpoint inhibitors (ICPi) have shown major therapeutic successes when used in various cancers. In the HIV field a double benefit of such ICPi should result from their dual ability to restore in-vitro HIV-specific CD8+ T-cell functions and to enhance HIV production from reservoir cells, thus fulfilling the goals of the ‘shock and kill’ concept proposed as an HIV cure therapeutic strategy. We conducted a systematic review to identify studies reporting the tolerance profile of ICPi and their effects on HIV plasma loads (pVL), CD4+ count, HIV reservoirs (cell-associated HIV-DNA) and/or HIV-specific CD8+ T in PLWH. Thirty-four articles were included for a total 176 participants. 12.1% participants experienced severe adverse events and 49.4% nonsevere adverse events. pVL remained stable in 91.9% participant, showed increases in 5.8% participant, and decreases in 2.3%. CD4+ count remained stable in 60.7% participants, showed increases in 24.6%, and decreases in 14.7%. Regarding ICPi effects on HIV-DNA and HIV-specific immunity, we identified three distinct profiles: profile I, transient pVL increases followed by a boost in HIV-specific CD8+ T cells concomitant to a decrease in HIV-DNA, reported in one participant. Profile II: increase in HIV-specific CD8+ T cells without changes in pVL or HIV-DNA, reported in three participants. III: no effect, reported in five participants. In conclusion, the clinical, virological and immunological safety profiles of ICPi reported in about 200 PLWH appear to be favorable but their still modest results in terms of HIV cure strategy.Keywords
This publication has 71 references indexed in Scilit:
- Interleukin-7 promotes HIV persistence during antiretroviral therapyBlood, 2013
- Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsThe Lancet, 2013
- Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter StudyClinical Infectious Diseases, 2012
- Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus ReactivationImmunity, 2012
- Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic MelanomaJournal of Clinical Oncology, 2011
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunctionNature Immunology, 2007
- Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunctionNature Medicine, 2006
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature, 2006
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005